Livagen
Also called KEDA; Lys-Glu-Asp-Ala
A four-amino-acid bioregulator peptide studied mainly in lab models of chromatin, protein synthesis and digestive enzymes. Calling it a "liver peptide" is not evidence that it treats liver disease.
Overview
What it is
A synthetic tetrapeptide designed from liver polypeptide data. It is not a liver extract and is different from Ovagen.
How it works
In immune cells from older donors grown in culture, it loosened DNA packaging (chromatin) and activated ribosomal genes. That is not the same as repairing DNA or reversing aging.
What the research shows
In rat liver cells, it increased protein synthesis, most in cells from older animals. Oral Livagen changed digestive enzyme activity in opposite directions in young and old rats. An early Russian patent described 23 hepatitis patients with symptom and lab changes, without randomization or blinding.
Studied for
- Chromatin in older donors' immune cellslab
- Liver cell protein synthesisrats
- Digestive enzymesrats
Safety and regulatory status
Safety and side effects
No reliable human side-effect rate, long-term safety or drug interaction data. Abnormal liver tests need medical evaluation to find the cause.
Regulatory status
Not approved by the FDA for any use.
Mixing and dosing reference
Reference information only. Read before using this section.
Livagen (20 mg Vial) Dosage Protocol
- Vial
- 20 mg Livagen
- Add diluent
- 3 mL
- Concentration
- 6.67 mg/mL
- 1 unit (U-100)
- 66.67 mcg in 0.01 mL
- Route
- Subcutaneous
- How often
- Once per day (subcutaneous).
- Typical range
- 0.5–2.0 mg once daily (gradual titration over 8–12 weeks).
- Cycle length
- 8–12 weeks; optional extension to 16 weeks.
Standard / Gradual Approach
| Week | Daily Dose (mg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 0.5 mg (500 mcg) | 7.5 units (0.075 mL) |
| Weeks 3–4 | 1.0 mg (1000 mcg) | 15 units (0.15 mL) |
| Weeks 5–6 | 1.5 mg (1500 mcg) | 22.5 units (0.225 mL) |
| Weeks 7–12 | 2.0 mg (2000 mcg) | 30 units (0.30 mL) |
How to mix
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Dosing details
- Start: 0.5 mg daily; increase by ~0.5 mg every 1–2 weeks as tolerated.
- Target: 1.5–2.0 mg daily by Weeks 5–12.
- Frequency: Once per day (subcutaneous).
- Cycle Length: 8–12 weeks; optional extension to 16 weeks.
- Timing: Any consistent time; rotate injection sites.
Storage
- Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); prepare aliquots if needed and avoid freeze–thaw.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Administration technique
- Clean the vial stopper and skin with alcohol; allow to dry.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.
- Do not aspirate for subcutaneous injections; inject slowly and steadily.
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.
- Dispose of used syringes immediately in a sharps container.
Important notes
- Use new sterile insulin syringes; dispose in a sharps container.
- Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
- Inject slowly; wait a few seconds before withdrawing the needle.
- Document daily dose and site rotation to maintain consistency.
- No standardized human clinical administration studies exist for Livagen; dosing is extrapolated from preclinical data and similar peptide bioregulators.
Protocol source: PeptideDosages.com
Common questions
Is Livagen an anti-aging peptide?
It is studied in aging research, but has not been shown to extend life or restore organ function.
Is Livagen the same as Ovagen?
No. They are different peptides.
What should I do about abnormal liver tests?
See a clinician to find the cause, such as infection, alcohol, metabolic disease or medications.
Related in Healthy Aging
Sources and further reading (5)
- Brodskii VIa, et al. Protein synthesis in hepatocytes from rats of different ages: effect of Livagen, 2001.
- Khavinson VKh, et al. Livagen and chromatin activation in lymphocytes from old people. Bull Exp Biol Med, 2002.
- Timofeeva NM, et al. Livagen and digestive enzymes in rats of different ages. Adv Gerontol, 2005.
- NIDDK. Liver disease.
- Source summary: PeptideDosages.com research overview (rewritten for NVO).